An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment / M. Gentile, T.D. Shanafelt, F.R. Mauro, G. Reda, D. Rossi, L. Laurenti, M.I. Del Principe, G. Cutrona, I. Angeletti, M. Coscia, Y. Herishanu, A. Chiarenza, S. Molica, S. Ciolli, N. Goldschmidt, F. Angrilli, A. Giordano, A. Rago, O. Bairey, G. Tripepi, K.G. Chaffee, P.A. Sameer, E. Vigna, K. Zirlik, L. Shvidel, I. Innocenti, A.G. Recchia, F. Di Raimondo, G. Del Poeta, A. Cortelezzi, A. Neri, M. Ferrarini, G. Gaidano, N.E. Kay, A. Polliack, R. Foà, F. Morabito. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - 101:5(2018 Nov), pp. 703-706. [10.1111/ejh.13149]
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
G. Reda;A. Cortelezzi;A. Neri;
2018
Abstract
An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.File | Dimensione | Formato | |
---|---|---|---|
Gentile_Eur.J.Haematol_2018.pdf
Open Access dal 10/01/2020
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
325.46 kB
Formato
Adobe PDF
|
325.46 kB | Adobe PDF | Visualizza/Apri |
Gentile_et_al-2018-European_Journal_of_Haematology.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
343 kB
Formato
Adobe PDF
|
343 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.